ReviewFrontiers in cardiovascular medicine2026
Residual risk in cardiovascular and renal diseases and the potential role of aldosterone synthase inhibitors.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renin-angiotensin-aldosterone system (RAAS) blockade has been a mainstay of therapy in cardiovascular and kidney disease for nearly 30 years. Despite the development of multiple drug classes designed to intervene along the RAAS pathway, the residual risk for the totality of adverse cardiorenal outcomes (cardiorenal disease) remains substantial. Dysregulation of aldosterone biosynthesis has pathophysiological consequences that are associated with cardiovascular and kidney damage. Aldosterone synthase inhibitors (ASi) provide a mechanism to decrease aldosterone production. These agents may help to reduce residual risk in cardiorenal disease. Preliminary evidence from ASi clinical trials is encouraging, with demonstrated efficacy in improving blood pressure control and decreasing albuminuria in chronic kidney disease. Their therapeutic potential in improving cardiorenal outcomes is being investigated further in ongoing phase III trials where ASi agents are given as monotherapy or with an SGLT2 inhibitor, and these data will be available over the coming months and years. ASi agents may be a new evidence-based addition to the cardiorenal drug armamentarium.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.